SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hirsh J. Oral Anticoagulant drugs. N Engl J Med 1991; 324: 156574.
  • 2
    Hirsh J. Heparin. N Engl J Med 1991; 324: 186575.
  • 3
    Warkentin TE, Greinhacher A, Koster A, Linkoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physician evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 340S80S.
  • 4
    Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physician evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 160S98S.
  • 5
    Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physician evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 141S59S.
  • 6
    Weitz JL. Low-molecular-weight heparin. N Engl J Med 1997; 337: 68898.
  • 7
    Hirsh J, O'Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 2007; 116: 55260.
  • 8
    Monroe DM. Basic principles undelying coagulation. In: Practical Hemostasis and Thrombosis, 2nd edn. eds Key N, Makris M, O'Shaughnessy D, Lillicrapt D. Oxford: Wiley-Blackwell, 2009; 16.
  • 9
    Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003; 1: 150414.
  • 10
    Hirsh J, O'Donnell M, Weitz JL. New anticoagulants. Blood 2005; 105: 45363.
  • 11
    Weitz JL, Bates SM. New anticoagulants. J Thromb Haemost 2005; 3: 184353.
  • 12
    Harenberg J. Development of new anticoagulants: present and future. Semin Thromb Haemost 2008; 34: 77993.
  • 13
    Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Haemost 2008; 34: 77993.
  • 14
    Toschi V, Lettino M. Fondaparinux: pharmacology and clinical experence in cardiovascular medicine. Mini Rev Med Chem 2007; 7: 3837.
  • 15
    Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs. enoxaparin for the prevention of venous thromboembolism in major orthopaedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002; 162: 183340.
  • 16
    Eriksson BI, Lassen MR. PENTsaccharide in Hip-Fracture Surgery Plus Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003; 163: 173342.
  • 17
    Büller HR, Davidson BL, Decousus H, Gallus AS, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW, MATISSE Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140: 86773.
  • 18
    The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695702.
  • 19
    Decousus H, Prandoni P, Mismetti P, Bauersachs RM, Boda Z, Brenner B, Laporte S, Matyas L, Middeldorp S, Sokurenko G, Leizorovicz A, for the CALISTO Study Group. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med 2010; 363: 122232.
  • 20
    Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA, Fifth Organization to Assess Strategies in Acute Coronary Syndromes Investivators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 146476.
  • 21
    Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, KA F, OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006; 295: 151930.
  • 22
    Mehta SR, Boden WE, Eikelboom JW, Flather M, Steg PG, Avezum A, Afzal R, Piegas LS, Faxon DP, Widimsky P, Budaj A, Chrolavicius S, Rupprecht HJ, Jolly S, Granger CB, Fox KA, Yusuf S, OASIS 5 and 6 Investigators. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation 2008; 118: 203846.
  • 23
    Warkentin TE, Cook RJ, Marder VJ, Sheppard JA, Moore JC, Eriksson BI, Greinacher A, Kelton JG. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005; 106: 37916.
  • 24
    Warkentin TE. Fondaparinux: does it cause HIT? Can it treat HIT? Expert Rev Hematol 2010; 3: 56781.
  • 25
    Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Haemost 2008; 34: 3957.
  • 26
    Harenberg J, Vukoievic Y, Milkus G, Joerg I, Weiss C. Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials. J Thromb Haemost 2008; 6: 8902.
  • 27
    Savi P, Herault JP, Duchaussoy P, Millet L, Schaeffer P, Petitou M, Bono F, Herbert JM. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J Thromb Haemost 2008; 6: 1697706.
  • 28
    Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE, The van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357: 1094104.
  • 29
    Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE, The van Gogh Investigators. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007; 357: 1105112.
  • 30
    Bousser MG, Bouthier J, Buller HR, Cohen AT, Crijns H, Davidson BL, Halperin J, Hankey G, Levy S, Pengo V, Prandoni P, Prins MH, Tomkowski W, Torp-Pedersen C, Wyse DG, Amadeus Investigators. Comparison of idraparinux with vitamn k antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomized, open-label, non-inferiority trial. Lancet 2008; 371: 31521.
  • 31
    Buller HR, Destors JM, Gallus AS, Pillion G, Prins MH, Raskob JE, The Equinox investigators. Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. J Thromb Haemost 2011; 9: 922.
  • 32
    Paty I, Trellu M, Destors JM, Cortez P, Boëlle E, Sanderink G. Reversibility of the anti-FXa activity of idrabiotaparinux (biotynilated idraparinux) by intravenous avidin infusion. J Thromb Haemost 2010; 8: 7229.
  • 33
    Guertin KR, Choi YM. The discovery of the factor Xa inhibitor otamixaban: from the lead identification to clinical development. Curr Med Chem 2007; 14: 247181.
  • 34
    Eikelboom JW, Weitz JL. Otamixaban in acute coronary syndromes. Lancet 2009; 374: 7624.
  • 35
    Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, Saaiman A, Polasek R, Contant CF, McCabe CH, Braunwald E. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomized, double-blind, active-controlled, phase 2 trial. Lancet 2009; 347: 78795.
  • 36
    Eikelboom JW, Weitz JI. Update on antithrombotic therapy. New anticoagulants. Circulation 2010; 121: 152332.
  • 37
    Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamic, and pharmacokinetics of single dose of BAY 59-7939, an oral direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 41221.
  • 38
    Eriksson BI, Quinlan DJ, Weitz JL. Comparative pharmacodynamic and pharmacokinetic of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48: 122.
  • 39
    Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmakodynamics, and pharmacokinetics of rivaroxaban – an oral, direct Factor Xa inhibitor – are not affected by aspirin. J Clin Pharmacol 2006; 46: 98190.
  • 40
    Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – has no clinical relevant interaction with naproxen. Br J Clin Pharmacol 2007; 63: 46976.
  • 41
    Weitz JI. New oral anticoagulants in development. Thromb Haemost 2010; 103: 6270.
  • 42
    Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kalebo P, Misselwitz F, Gent M. BAY 59-793: an oral, direct, factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement: a phase II dose-ranging study. J Thromb Haemost 2005; 3: 247986.
  • 43
    Eriksson BI, Borris LC, Dahal OE, Haas S, Huismann MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kalebo P. A once-daily, oral, direct factor Xa, inhibitor, rivaroxaban (BAY 59-793), for thromboprophylaxis after total hip replacement. Circulation 2006; 114: 237481.
  • 44
    Eriksson BI, Borris L, Dahal OE, Haas S, Huismann MV, Kakkar AK, Misselwitz F, Kalebo P. Oral, direct factor Xa, inhibition with BAY 59-793 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006; 4: 1218.
  • 45
    Eriksson BI, Borris LC, Friedman RJ, Haas S, Huismann MV, Kakkar AK, Bander TJ, Beckman H, Muehlhofer E, Misselwitz F, Geertz W. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 276575.
  • 46
    Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip artroplasty: a double blind, randomized controlled trial. Lancet 2008; 372: 319.
  • 47
    Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosemberg N, Bandel TJ, Misselwitz F, Turpie AG. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee artroplasty. N Engl J Med 2008; 358: 277686.
  • 48
    Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee artroplasty (RECORD 4): a randomized trial. Lancet 2009; 373: 167380.
  • 49
    Gomez-Outez A, Suárez-Gea ML, Blásquez-Perez A, Pozo-Hernández C, Vargas-Castrillón E. Will oral rivaroxaban improve clinically relevant outcomes and thromboprophylaxis in the orthopaedic patients? J Thromb Haemost 2009; 7: 214950.
  • 50
    Huisman MV, Quinlan DJ, Dahl OE, Schulman S. Enoxaparin versus dabigatran or rivaroxaban for the thromboprophylaxis after hip or knee arthroplasty: results of separate pooled analysis of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes 2010; 3: 65260.
  • 51
    Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S, ODIXa-DVT Study Investigators. Treatment of proximal deep –vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic Deep-Vein Trombosis) Study. Circulation 2007; 116: 1807.
  • 52
    Franchini M, Mannucci PM. A new era for anticoagulants. Eur J Int Med 2009; 20: 5628.
  • 53
    Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A, Einstein-DVT Dose-Ranging Study Investigators. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008; 112: 22427.
  • 54
    Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus A, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Well P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S, The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499510.
  • 55
    Mega J, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V Barnathan ES, Bordes P, Witkowsky A, Markov V, Oppenheimer R, Gibson CM, ATLAS ACS-TIMI 46 Study Group. Rivaroxaban versus placebo in patients with acute coronary syndrome (ATLAS ACS-TIMI 46): a randomized, double-blind, phase II trial. Lancet 2009; 374: 2938.
  • 56
    Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct, factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Heamost 2007; 5: 236875.
  • 57
    Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxix after knee replacement. N Engl J Med 2009; 361: 594604.
  • 58
    Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P, ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial. Lancet 2010; 375: 80715.
  • 59
    Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Ramirez LM, ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 248798.
  • 60
    Buller H, Deitchman D, Prins M, Segers A, Botticelli investigators Writing Committee. Efficacy and safety of the oral factor Xa inhibitor for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6: 13138.
  • 61
    Conolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, Fleker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budai A, Parkhomenko A, Janski P, Commerford P, Tan RU, Sim K-H, Lewis BS, Van Mieghem W, Lip GYH, Kim JH, Lanas-Zanetti F, Gonzales-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S, for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 80617.
  • 62
    Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Werheugt F, Wallentin L, APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009; 119: 287785.
  • 63
    Chung N, Jeon HK, Lai WT, Tse HS, Chung WS, Lee TH, Chen SA. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thromb Haemost 2011; 105: 53545.
  • 64
    Viskov C, Just M, Laux V, Mourier P, Lorenz M. Description of the chemical and pharmacological characteristic of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026. J Thromb Haemost 2009; 7: 114351.
  • 65
    Dubruc C, Karimi-Anderesi N, Lunven C, Zhang M, Grossmann M, Potgieter H. Pharmacokinetics of a new, ultra-low molecular weight heparin, semuloparin (AVE5026), in healthy subjects. Results from the phase I studies. 51st ASH Annual Meeting. Blood (ASH Annual Meeting Abstracts) 2009; 114: Abstract 1073.
  • 66
    Lassen MR, Dahl OE, Mismetti P, Destrée D, Turpie AG. AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery – TREK: a dose ranging study. J Thromb Haemost 2009; 7: 56672.
  • 67
    Gomez-Outes A, Suárez-Gea ML, Lecumberri R, Rocha E, Pozo-Hernández C, Vargas-Castrillón E. New parenteral anticoagulants in development. Ther Adv Cardiovasc Dis 2011; 5: 3359.
  • 68
    Kishimoto TK, Qi YW, Long A, Capila I, Sasisekhan R, Guerrero L, Fier I, Roach J, Venkataraman G. M118 – a rationally low-molecular-weight-heparin designed specifically for the tratment of acute coronary syndromes. Thromb Hemost 2009; 102: 9006.
  • 69
    Rao SV, Molloni C, Myles-DiMauro S, Broderick S, Kosinsky AS, Kleiman NS, Dzavík V, Tanguay JF, Chandna H, Gammon R, Rivera E, Alexander JH, Fier I, Roach J, Becker RC, for the EMINENCE Investigators. Evaluation of a new heparin agent in percutaneous coronary intervention. Results of the phase 2 Evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) trial. Circulation 2010; 121: 171321.
  • 70
    Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006; 96: 27484.
  • 71
    Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009; 48: 122.
  • 72
    Turpie AGG, Bauer KA, Davidson BL, Fisher WD, Gent M, Huo MH, Sinha U, Gretel DD, for the EXPERT Study Group. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thrombo-embolic events after total knee replacement (EXPERT). Thromb Haemost 2009; 101: 6876.
  • 73
    Schirmer SH, Baumhäkel M, Neuberger H-R, Hohnloser SH, van Gelder IC, Lip HYH, Böhm M. Novel anticoagulants for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2010; 56: 206776.
  • 74
    Mehta RS. Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: part I (Factor Xa inhibitors). Exp Rev Hematol 2010; 3: 22741.
  • 75
    Cohen AT, Armstrong D, Gazdzig T, Ryge C, Pak R, Mandema J, Boyd R, McBridge S, DiCarlo LA. An adaptive design dose-ranging study of PD 0348292, a novel oral Factor Xa inhibitor, for the prophylaxis after total knee replacement study. 50th ASH Annual Meeting. Blood (ASH Annual Meeting Abstracts) 2008; 112: Abstract 980.
  • 76
    Kaku S, Suzuki K-I, Funatsu T, Saitoh M, Hiroyuki K, Ishihara T, Hirayama F, Kawasaky T. Effects of direct factor Xa inhibitor, YM150, on clot formation and clot lysis in vitro compared with other anticoagulants. 49th ASH Annual Meeting. Blood (ASH Annual Meeting Abstracts) 2007; 110: Abstract 3153.
  • 77
    Saitoh M, Kaku S, Funatsu T, Koshio H, Ishihara T, Hirayama F, Kawasaky T, Sasamata M. Comparison of YM150, an oral, direct factor Xa inhibitor, with other antithrombotic agents in rodent venous and arterial thrombosis model. 49th ASH Annual Meeting. Blood (ASH Annual Meeting Abstracts) 2007; 110: Abstract 3155.
  • 78
    Iwatsuki Y, Shigenaga T, Moritani S, Ishihara T, Hirayama F, Kawasaky T. Biochemical and pharmacological prophiles of YM150, an oral direct factor Xa inhibitor. 48th ASH Annual Meeting. Blood (ASH Annual Meeting Abstracts) 2006; 108: Abstract 911.
  • 79
    Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kälebo P, Gaillard ML, Meems L, for the ONYX Study Group. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2010; 5: 16605.
  • 80
    Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kälebo P, Wetherrill G, Wilpshaar JW, Meems L, for the ONYX-2 Study Group. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J Thromb Haemost 2010; 8: 71421.
  • 81
    Konishi N, Hiroe K, Kawamura M. Differential effects of TAK-442, a novel orally active factor Xa inhibitor, and ximelagatran, a thrombin unhibitor, on factor V-mediated feedback on coagulation cascade and bleeding. Thromb Haemost 2010; 104: 50413.
  • 82
    Stringer F, Scott G, Kupfer S, Cao C, Kawamura M. Absence of pharmacodynamic or pharmacokinetic interactions when TAK-442, an oral direct factor Xa inhibitor, is coadministred with aspirin or clopidogrel. 51st ASH Annual Meeting. Blood (ASH Annual Meeting Abstracts) 2009; 114: Abstract 4175.
  • 83
    Konishi N, Hiroe K, Kawamura M. Synergistic effect of factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats. Thromb Res 2010; 126: 1249.
  • 84
    Konishi N, Hiroe K, Kawamura M. Effect of fondaparinux and a direct FXa inhibitor TAK-442, on platelet-associated prothrombinase in the ballon-injured artery of rats. J Cardiovasc Pharmacol 2011; 57: 2016.
  • 85
    Weitz JI, Cao C, Eriksson BI, Fisher W, Kupfer S, Raskob G, Spaeder J. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost 2010; 104: 11507.
  • 86
    Hartman DL, Bernard GR, Helterbrand JD, Yan SB, Fisher CJ. Recombinant human activated protein C (RhAPC) improves coagulation abnormalities associated with severe sepsis. Intensive Care Ned 1998; 24 (Suppl. 1): S77 [Abstract].
  • 87
    Bernard GR, Vincent J-L, Laterre P-F, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrans JD, Ely EW, Fisher CJ, for the Recombinat Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. N Engl J Med 2001; 344: 699709.
  • 88
    Martin G, Brunkhorst FM, Janes JM, Reinhart K, Sundin DP, Garnett K, Beale R. The International PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patients outcome. Crit Care 2009; 13: R103; doi: 10.11.86/cc7936.
  • 89
    Geerts H, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venous thromboembolism: American College of Chest Physician evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 381S453S.
  • 90
    Levi M, Levy M, Williams MD, Antonelli M, Wang D, Mignini MA. Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis. Intensive Care Med 2009; 35: 1196203.
  • 91
    Shorr AF, Williams MD. Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis. Thromb Haemost 2009; 101: 13944.
  • 92
    Nakashima M, Kanamaru M, Umemura K, Tsuruta K. Pharmacokinetics and safety of a novel recombinant soluble human thrombomodulin, ART-123, in healthy male volunteers. J Clin Pharmacol 1998; 38: 404.
  • 93
    Moll S, Lindley C, Pescatore S, Morrison D, Tsuruta K, Mohri M, Serada M, Sata M, Shimizu H, Yamada K, White GC. Phase I study of a novel recombinant human soluble thrombomodulin, ART-123. J Thromb Haemost 2004; 2: 174551.
  • 94
    Kearon C, Comp P, Douketis J, Royds R, Yamada K, Gent M. Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2005; 3: 9628.
  • 95
    Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M, Aoki N. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomised, double-blind clinical trial. J Thromb Haemost 2007; 5: 3141.